A study on treatment results for hepatorenal syndrome
Part of Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks back at medical records of people who had hepatorenal syndrome (a type of kidney failure linked to liver disease) while in the hospital. The goal is to understand what treatments were used and how well patients did, which might help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were hospitalized between April 2019 and April 2023.
- You had a type of kidney failure called HRS-AKI (hepatorenal syndrome with acute kidney injury) when you came to the hospital or developed it during your stay.
- You have cirrhosis (scarring of the liver), acute liver failure, or a sudden worsening of chronic liver disease.
- You had a sudden rise in creatinine (a kidney function marker) or low urine output that did not improve after stopping diuretics and trying fluids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a liver procedure called TIPS can help people with cirrhosis who develop sudden kidney failure (HRS-AKI). It aims to improve kidney function and overall outcomes, but participation depends on several safety checks.
This study checks new blood and urine tests to predict who with advanced liver scarring (cirrhosis) will develop hepatorenal syndrome, a serious kidney problem. The results may help doctors spot risk earlier, especially for people being referred for a liver transplant.
This study looks at kidney tissue from patients having a liver transplant to understand and improve treatment for a kidney problem called hepatorenal syndrome. It may help doctors find better ways to protect kidney function after transplant.
This study looks for blood markers that may predict heart and kidney problems in people with stable chronic heart failure. If you have heart failure and are willing to give blood samples, you may help researchers better understand and manage this condition.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This study tests if using ultrasound scans to guide fluid removal helps protect kidney function in people with cardiorenal syndrome type 1, where heart failure suddenly worsens kidney function.
Hear when a new Hepatorenal Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.